The Department of Health and Human Services on Friday endorsed the Drug Enforcement Administration’s effort to place synthetic kratom extracts under federal control, aligning with a move to regulate products sometimes called the “gas station opioid.”
According to federal officials, the DEA in July announced plans to temporarily schedule a psychoactive compound derived from kratom, citing concerns about safety and misuse. HHS added its recommendations in support of that action, a required step in the federal scheduling process.
Kratom is a plant native to Southeast Asia. Public health authorities note that the current push targets laboratory-made compounds or chemically altered extracts, not the raw plant itself.
Regulators say these synthetic or highly concentrated products have been marketed widely, including at convenience stores, often without consistent quality controls or age restrictions. The action comes as federal agencies weigh broader policy issues that have also surfaced in recent debates over the politics of tariffs after Trump and other national regulatory fights.
HHS’s endorsement signals agreement that the extracts meet the standard for temporary placement on the federal schedules while a full review proceeds. Temporary scheduling allows DEA to restrict distribution and possession as it evaluates health risks, potential for abuse, and accepted medical use.
Officials said the recommendation follows reports of adverse events and rising availability of potent kratom-derived products. The scheduling proposal would not resolve state-by-state rules, but it would set a nationwide baseline for enforcement against the targeted compounds.
What scheduling synthetic kratom extracts would do
If finalized, temporary scheduling would limit manufacturing, sales, and possession of the identified compounds, and could require registrations for research. Retailers could face penalties for selling covered products, including those found in convenience stores and online.
Health agencies emphasized that consumers should check labels carefully and avoid unregulated products, particularly those marketed as legal alternatives to opioids or as performance enhancers. Federal officials pointed to ongoing information from the Drug Enforcement Administration for guidance on controlled substances.
Hawaiʻi health officials have previously warned about unregulated supplements and smoke shop items sold to residents and visitors. The federal action would add tools for local and state authorities, including in Hawaiʻi, to curb distribution of the targeted extracts while longer-term assessments continue.
The DEA will take additional steps before the rule is finalized, including publishing notice and allowing for comment. No timeline was provided for completion of the full scheduling review, which will also involve ongoing consultation with the U.S. Department of Health and Human Services.
